Krishna Subramanian

Company: Seelos Therapeutics

Job title: Vice President & Head of Non-Clinical & Translational Science

Seminars:

Panel Discussion: Extrapolating Neurological Indications with the Greatest Potential to Leverage Intranasal Administration 9:00 am

Empowering opioid overdose, bipolar disorder, anxiety, depression and more with the potential advantages of nasal formulations, such as increased specificity and enhanced potency Brainstorming innovative approaches for quantifying subjective metrics like migraine pain relief, anosmia reduction, taste enhancement, and mood improvement for robust quality control Delving into anticipated advancements, concerning challenges and expected priorities across…Read more

day: Conference Day Two

Developing Nasal Formulations for Novel Indications – Acute Suicidal Ideation 3:30 pm

Understanding molecule PKPD and dose selection Administering your API intravenously vs nasally and the impact on your molecule for optimal results Evaluating toxicological challenges of intranasal CNS formulations for accelerated approvalRead more

day: Conference Day Two